Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point

On Tuesday, Exact Sciences Corp. (NASDAQ:EXAS) reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20.

The reported quarterly sales of $708.66 million missed the consensus estimate of $717.66 million.

Screening revenue was $545 million, an increase of 15%, and Precision Oncology’s revenue was $164 million, an increase of 5% on a reported and core revenue basis.

Also Read: FDA Clears Exact Sciences’ Next-Generation Colorectal Cancer Diagnostic Test.

“While we have made progress, our execution during the third quarter and updated outlook for the full year don’t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains ...